Lymphoma, Lymphoproliferative Syndrome, Autoimmune
Conditions
Brief summary
observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021
Detailed description
observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021. Study objectives are to enrich the data on the prognostic role of clinical and epidemiological factors associated with clinical and epidemiological data of patients; * to identify the factors that affect the evolution of the disease, such as lifestyle and occupational factors, as well as the type of treatment; * to provide a platform for future research projects; * Description of the various therapies that have occurred over time, duration of treatment, causes of interruption of treatment, responses; * Description of the adverse events / safety of the various therapies for lymphoma and lymphoproliferative syndromes; * Patient survival. Descriptive analyses will be conducted by tabulating frequency distributions and percentages and mean and median values, standard deviations, quartiles and extreme values for continuous variables. Progression-free survival, disease-free survival and overall survival will be examined using Kaplan-Meier point estimates
Interventions
None listed
Sponsors
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age greater than or equal to 18 years of enrollment * Diagnosis of lymphoma or lymphoproliferative syndrome between January 1980 and September 2021 * Signature of the informed consent form where applicable
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and prevalence of lymphomas/lymphoproliferative syndromes referred to the Centre between January 1980 and September 2021 | through study completion, an average of 6 years | Incidence and prevalence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| event free survival (EFS) | through study completion, an average of 6 years | event free survival (EFS) |
| Lymphoma specific survival (LSS) | through study completion, an average of 6 years | Lymphoma specific survival (LSS) |
| Progression Free Survival (PFS) | through study completion, an average of 6 years | Progression Free Survival (PFS) |
| Net survival (5 years) | through study completion, an average of 6 years | Net survival |
| Response rate (5 years) | through study completion, an average of 6 years | Response rate |
| Overall Survival (OS) | through study completion, an average of 6 years | Overall Survival (OS) |
| time to next anti-lymphoma treatment (TTNLT) | through study completion, an average of 6 years | time to next anti-lymphoma treatment (TTNLT) |
| Duration of survival after progression | through study completion, an average of 6 years | Duration of survival after progression |
| lymphoma transformation frequency | through study completion, an average of 6 years | lymphoma transformation frequency |
| Frequency of secondary neoplasy | through study completion, an average of 6 years | Frequency of secondary neoplasy |
| frequency of other chronic diseases | through study completion, an average of 6 years | frequency of other chronic diseases |
| Duration of Response (DoR) | through study completion, an average of 6 years | Duration of Response (DoR) |
Countries
Italy
Contacts
Primary ContactPier Luigi Zinzani, MD
Backup ContactAlessandro Broccoli, MD
Outcome results
None listed